I thought that is exactly where we are headed...another Phase 3 trial.
I assume that would require an FDA supervised trial, this time with more accurate and focused targets. If I understand it correctly, the trial won't need 18 months, but can be halted in 9 months if the data bears out what the earlier data indicated. With 9 months of data and 2,000 patients, you can populate the patient year requirements fairly easily. Presto, you then get a great Phase 3 trial, this time with kidney and heart and dementia properly accounted for.
As CS99 notes, this requires a big spend from a partner. An SGLT2 drug company should be happy to finance this. Eli Lilly, Pfizer, Merck, Jannsen, Boehringer...one of them should be easily roped in.
I suspect the virus has delayed all such negotiations. But the FDA will not wait...so the time pressure must be on potential partners to sign up.
Just my 2 cents.
Iconoclast